Literature DB >> 29695916

Investigation of LEP and LEPR polymorphisms with the risk of hepatocellular carcinoma: a case-control study in Eastern Chinese Han population.

Sheng Zhang1, Jiakai Jiang1, Zhan Chen2, Yafeng Wang3, Weifeng Tang2, Chao Liu4, Longgen Liu5, Yu Chen6,7,8.   

Abstract

BACKGROUND: Leptin (LEP) and LEP receptor (LEPR) polymorphisms may be associated with the development of cancer.
METHODS: In this study, we selected five functional LEP and LEPR single-nucleotide polymorphisms (SNPs) and conducted a case-control study to determine the relationship of LEP and LEPR polymorphisms with hepatocellular carcinoma (HCC) risk in Eastern Chinese Han population. There were 584 HCC cases and 923 cancer-free controls included in our study. HCC patients and controls were fully matched by age and sex. SNPscan™ genotyping method was used to analyze the genotyping of LEP rs2167270 G>A, rs7799039 A>G, LEPR rs6588147 G>A, rs1137100 G>A, and rs1137101 G>A SNPs.
RESULTS: We found that LEP rs7799039 A>G and rs2167270 G>A polymorphisms were associated with the susceptibility of HCC in this population (LEP rs7799039 A>G: GG vs AA: adjusted odds ratio [OR]=2.03, 95% CI, 1.22-3.38, P=0.006 and GG vs AA/AG: adjusted OR=1.97, 95% CI, 1.20-3.22, P=0.007; rs2167270 G>A: AA vs GG: adjusted OR=2.03, 95% CI, 1.10-3.75, P=0.024 and AA vs GG/GA: adjusted OR=2.01, 95% CI, 1.10-3.68, P=0.023). However, LEPR rs6588147 G>A polymorphism decreased the risk of HCC (GA vs GG: adjusted OR=0.62, 95% CI, 0.45-0.86, P=0.005 and AA/GA vs GG: adjusted OR=0.64, 95% CI, 0.47-0.88, P=0.007).
CONCLUSION: This case-control study highlights that LEP rs7799039 A>G and rs2167270 G>A polymorphisms increase the susceptibility to HCC; however, LEPR rs6588147 G>A polymorphism may be a protective factor for HCC in Eastern Chinese Han population.

Entities:  

Keywords:  LEP; LEPR; hepatitis B virus; hepatocellular carcinoma; polymorphism; risk; single nucleotide polymorphism

Year:  2018        PMID: 29695916      PMCID: PMC5905468          DOI: 10.2147/OTT.S153931

Source DB:  PubMed          Journal:  Onco Targets Ther        ISSN: 1178-6930            Impact factor:   4.147


Introduction

Liver cancer (LC) rates are the lowest in the South-Central areas of Asia and Northern, Central, and Eastern regions of Europe and the highest in East and South-East Asia and Northern and Western Africa.1 China alone accounts for about 50% of the total number of LC patients and LC-related deaths.1,2 Also, most of the LC patients have hepatocellular carcinoma (HCC). Although chronic hepatitis B virus (HBV) infection contributes to the major etiology of HCC,3 other risk factors may also influence the development of HCC. Nowadays, obesity and overweight are becoming a prevalent problem, which may increase the susceptibility to various cancers.4 Fatty liver is found commonly in patients with chronic HBV infection and might potentiate the risk of HBV-associated HCC by 7.3-fold.5 It is thought that metabolism-related gene may influence the risk of HCC. The excess of macronutrients stored results in overweight and obesity. Adipocytes may release many inflammatory mediators and lead to oxidative stress and proinflammatory states.6 Inflammatory and oxidative stress are related to the development of malignancy.7,8 Leptin (LEP) and LEP receptor (LEPR) may be implicated in various signal pathways, such as JAK/STAT, MAPK, PI3K, and mTOR.9 Also, these signal pathways were suggested to be correlated with carcinogenesis.10,11 Soga et al reported that fatty liver Shionogi-Lep/Lep mice developed hepatocellular adenomas and carcinomas following steatohepatitis.12 In addition, high levels of LEP were found in sera of patients with HCC.13 Thus, LEP and LEPR genes may impact on signal pathways and play an important role in the development of HCC. Recently, some important LEP and LEPR single-nucleotide polymorphisms (SNPs) were explored for the susceptibility to a number of cancers. LEP rs7799039 A>G, a promoter SNP, was suggested this variant was particularly affecting transcriptional level and LEP expression.14 However, LEP rs2167270 G>A is located in 5′-untranslated region and correlated with the translation process of LEP mRNA. Some previous meta-analyses suggested that LEP rs7799039 A>G and rs2167270 G>A variants conferred risk to cancer.15–17 However, the association of LEP rs7799039 A>G and rs2167270 G>A polymorphisms with HCC risk is unknown. LEPR rs1137100 G>A and rs1137101 G>A polymorphisms are two missense SNPs. Li et al reported that rs1137100 G>A and rs1137101 G>A polymorphisms in LEPR gene were correlated with susceptibility to HCC.18 In individuals with chronic HBV infection, these two LEPR SNPs may be a biomarker for the susceptibility to HCC.18 LEPR rs6588147 G>A is an intron SNP. Slattery et al found this SNP caused colon cancer susceptibility among men.19 In view of these previous studies, we found that the relationship of LEP and LEPR polymorphisms with the development of cancer was unclear, especially in Asians.20 In this study, we selected the LEP rs2167270 G>A, rs7799039 A>G, LEPR rs6588147 G>A, rs1137100 G>A, and rs1137101 G>A SNPs and conducted a case–control study to determine the relationship between LEP and LEPR polymorphisms and HCC risk in Eastern Chinese Han population.

Patients and methods

Subjects

This case–control study was performed on two groups. The patient group consisted of 584 HCC cases (mean age 53.17±11.76 years) who were selected from the Department of Hepatobiliary Surgery at Fuzong Clinical Medical College (Fuzhou city, China) and Union Clinical Medical College (Fuzhou city, China) of Fujian Medical University through 2002–2016. HCC diagnosis was confirmed by pathology. Two hepatobiliary surgeons independently evaluated the disease stage according to the criteria of Barcelona Clinic Liver Cancer (2010). The control group consisted of 923 cancer-free participants (mean age 53.72±9.97 years). Written informed consent was signed by each participant included in this study. Approval from the Ethics Committee of Fujian Medical University was obtained. Each participant donated a blood sample which was stored in an EDTA vacutainer tube.

DNA extraction and genotyping

The blood sample obtained from each participant was stored at −80°C immediately. Promega Genomic DNA Kit (Promega Corporation, Fitchburg, WI, USA) was used to extract and purify genomic DNA from lymphocytes. Purity and concentration of genomic DNA were determined by the NanoDrop ND-1000 spectrophotometer and 1.5% agarose gel electrophoresis. SNPscan™ genotyping method (Genesky Biotechologies Inc., Shanghai, China) was used to determine LEP rs2167270 G>A, rs7799039 A>G, LEPR rs6588147 G>A, rs1137100 G>A, and rs1137101 G>A genotypes. Sixty sample sizes (4%) were randomly selected for quality control. The genotyping was performed by our technicians and the results were not changed.

Statistical analysis

Data were analyzed by using SAS 9.4 software (SAS Institute, Cary, NC, USA). Continuous variables were expressed as mean±SD. Student’s t-test was used to assess the differences in age distribution. Chi-square (χ2) or Fisher’s exact test was used to assess the distribution of age, sex, chronic HBV infection status, smoking status, alcohol use, and genotypes. The deviation from Hardy–Weinberg equilibrium in the control group was determined by using an online calculator (http://ihg.gsf.de/cgi-bin/hw/hwa1.pl)21–25 to compare the observed genotype frequencies of LEP rs2167270 G>A, rs7799039 A>G, LEPR rs6588147 G>A, rs1137100 G>A, and rs1137101 G>A SNPs with the expected frequencies. Using additive, homozygote, dominant, and recessive models, the associations between LEP rs2167270 G>A, rs7799039 A>G, LEPR rs6588147 G>A, rs1137100 G>A, and rs1137101 G>A SNPs and susceptibility of HCC were assessed by crude/adjusted odds ratios (ORs) and confidence intervals (CIs). A P<0.05 (two-tailed) was considered as the threshold for statistical significance. In this study, a Bonferroni correction method was used for multiple testing.26,27

Results

Baseline characteristics

There were 584 HCC cases and 923 cancer-free controls included in our study. The frequency distributions for age, sex, chronic HBV infection status, smoking, and alcohol use among HCC patients and controls are summarized in Table 1. The characteristics of HCC cases and controls were fully matched by age and sex. The locus information of LEP rs2167270 G>A, rs7799039 A>G, LEPR rs6588147 G>A, rs1137100 G>A, and rs1137101 G>A polymorphisms is shown in Table 2. The genotyping success rate for all SNPs was eligible (>99%). Minor allele frequency of these SNPs was similar to the data of Chinese population. For these included SNPs, the genotype distribution in controls conformed to Hardy–Weinberg equilibrium.
Table 1

Distribution of selected demographic variables and risk factors in HCC cases and controls

VariablesCases (n=584)Controls (n=923)P-valuea
n%n%
Age (years)53.17 (±11.76)53.72 (±9.97)0.327
Age (years)0.358
 <5326445.2139542.80
 ≥5332054.7952857.20
Sex0.717
 Male52589.9083590.47
 Female5910.10889.53
Smoking status0.834
 Never37464.0459664.57
 Ever21035.9632735.43
Alcohol use<0.001
 Never41470.8977583.97
 Ever17029.1114816.03
Chronic HBV infection<0.001
 Yes41270.55859.21
 No17229.4583890.79
BCLC classification
 A39267.12
 B17529.97
 C172.91

Note:

Two-sided χ2-test and Student’s t-test.

Abbreviations: BCLC, Barcelona Clinic Liver Cancer; HBV, hepatitis B virus; HCC, hepatocellular carcinoma.

Table 2

Primary information for LEP rs2167270 G>A, rs7799039 A>G, LEPR rs6588147 G>A, rs1137100 G>A, and rs1137101 G>A polymorphisms

Genotyped SNPsChromosomeChr Pos (NCBI Build 37)RegionMAF for Chinese in databaseMAF in our controls (n=923)P-value for HWE test in our controlsGenotyping methodGenotyping value (%)
LEP rs7799039 A>G7127878783Promoter0.2010.2560.439SNPscan99.27
LEP rs2167270 G>A71278813495′ UTR0.1750.2130.245SNPscan99.27
LEPR rs1137100 G>A166036441Exon 40.1690.1550.203SNPscan99.27
LEPR rs1137101 G>A166058513Exon 60.1110.1160.453SNPscan99.20
LEPR rs6588147 G>A165935494Intron 20.1500.1490.097SNPscan99.27

Abbreviations: HWE, Hardy–Weinberg equilibrium; MAF, minor allele frequency; UTR, untranslated region.

Association of LEP rs2167270 G>A, rs7799039 A>G, LEPR rs6588147 G>A, rs1137100 G>A, and rs1137101 G>A polymorphisms with the risk of HCC

Table 3 lists the genotype distribution of LEP rs2167270 G>A, rs7799039 A>G, LEPR rs6588147 G>A, rs1137100 G>A, and rs1137101 G>A polymorphisms.
Table 3

Logistic regression analyses of association between LEP rs2167270 G>A, rs7799039 A>G, LEPR rs6588147 G>A, rs1137100 G>A, and rs1137101 G>A SNPs and the risk of HCC

GenotypeCases (n=584)
Controls (n=923)
Crude OR (95% CI)P-valueAdjusted ORa (95% CI)P-value
n%n%
LEP rs7799039 A>G
 AA29551.3050554.831.001.00
 AG22138.4336039.091.02 (0.82–1.28)0.8341.11 (0.83–1.48)0.498
 GG5910.26566.081.76 (1.19–2.60)0.0052.03 (1.22–3.38)0.006
 AG+GG28048.7041645.171.15 (0.94–1.42)0.1831.25 (0.95–1.65)0.110
 AA+AG51689.7486593.921.001.00
 GG5910.26566.081.77 (1.21–2.59)0.0041.97 (1.20–3.22)0.007
 G allele33929.4847225.62
LEP rs2167270 G>A
 GG34359.6556461.241.001.00
 GA19834.4332134.850.99 (0.80–1.24)0.9421.04 (0.78–1.40)0.774
 AA345.91363.911.52 (0.93–2.47)0.0932.03 (1.10–3.75)0.024
 GA+AA23240.3535738.761.07 (0.86–1.32)0.5411.15 (0.87–1.53)0.316
 GG+GA54194.0988596.091.001.00
 AA345.91363.911.55 (0.96–2.50)0.0762.01 (1.10–3.68)0.023
 A allele26623.1339321.34
LEPR rs6588147 G>A
 GG44477.2266171.771.001.00
 GA12321.3924626.710.73 (0.57–0.94)0.0130.62 (0.45–0.86)0.005
 AA81.39141.520.84 (0.35–2.01)0.6900.85 (0.27–2.69)0.777
 GA+AA13122.7826028.230.75 (0.59–0.96)0.0200.64 (0.47–0.88)0.007
 GG+GA56798.6190798.481.001.00
 AA81.39141.520.92 (0.38–2.20)0.8420.96 (0.31–3.03)0.947
 A allele13912.0927414.88
LEPR rs1137100 G>A
 GG42473.7465370.901.001.00
 GA14324.8725127.250.86 (0.68–1.09)0.2220.75 (0.55–1.03)0.074
 AA81.39171.850.71 (0.31–1.66)0.4330.62 (0.20–1.92)0.408
 GA+AA15126.2626829.100.87 (0.69–1.10)0.2350.75 (0.55–1.02)0.069
 GG+GA56798.6190498.151.001.00
 AA81.39171.850.75 (0.32–1.75)0.5060.68 (0.22–2.07)0.496
 A allele15927.6528515.47
LEPR rs1137101 G>A
 GG45378.7871777.931.001.00
 GA11920.7019320.980.96 (0.74–1.24)0.7610.81 (0.58–1.14)0.230
 AA30.52101.090.47 (0.13–1.71)0.2510.22 (0.05–1.10)0.065
 GA+AA12221.2220322.070.95 (0.74–1.23)0.7000.78 (0.56–1.09)0.152
 GG+GA57299.4891098.911.001.00
 AA30.52101.090.48 (0.13–1.74)0.2640.24 (0.05–1.16)0.076
 A allele12510.8721311.58

Notes:

Adjusted for age, sex, smoking status, alcohol use, and chronic HBV infection status. Bold values are statistically significant (P<0.05).

Abbreviations: HBV, hepatitis B virus; HCC, hepatocellular carcinoma; LEP, leptin; LEPR, LEP receptor; OR, odds ratio; SNPs, single-nucleotide polymorphisms.

Frequencies of LEP rs7799039 AA, AG, and GG genotypes were 51.30%, 38.43%, and 10.26% in HCC cases and 54.83%, 39.09%, and 6.08% in controls, respectively. When compared with the frequency of LEP rs7799039 AA genotype, a significant difference was found in the frequency of LEP rs7799039 GG genotype between HCC cases and controls (crude OR=1.76, 95% CI, 1.19–2.60, P=0.005). When compared with frequency of LEP rs7799039 AA/AG genotype, there was a difference in the frequency of LEP rs7799039 GG genotype between HCC patients and controls (crude OR=1.77, 95% CI, 1.21–2.59, P=0.004). Adjustments for age, sex, chronic HBV infection status, smoking, and drinking, this association was not essentially changed (GG vs AA: adjusted OR=2.03, 95% CI, 1.22–3.38, P=0.006 and GG vs AA/AG: adjusted OR=1.97, 95% CI, 1.20–3.22, P=0.007; Table 3). Frequencies of LEP rs2167270 GG, GA, and AA genotypes were 59.65%, 34.43%, and 5.91% in HCC patients and 61.24%, 34.85%, and 3.91% in controls, respectively. The association between LEP rs2167270 G>A polymorphism and a tendency for increased HCC risk was noted (AA vs GG: crude OR=1.52, 95% CI, 0.93–2.47, P=0.093 and AA vs GG/GA: crude OR=1.55, 95% CI, 0.96–2.50, P=0.076). Adjustments for age, sex, chronic HBV infection status, smoking, and drinking, this association was more significant (AA vs GG: adjusted OR=2.03, 95% CI, 1.10–3.75, P=0.024 and AA vs GG/GA: adjusted OR=2.01, 95% CI, 1.10–3.68, P=0.023; Table 3). Frequencies of LEPR rs6588147 GG, GA, and AA genotypes were 77.22%, 21.39%, and 1.39% in HCC patients and 71.77%, 26.71%, and 1.52% in controls, respectively. When compared with the frequency of LEPR rs6588147 GG genotype, a significant difference was found in the frequency of LEPR rs6588147 GA genotype between HCC cases and controls (crude OR=0.73, 95% CI, 0.57–0.94, P=0.013). When compared with the frequency of LEPR rs6588147 GG genotype, there was a difference in the frequency of LEPR rs6588147 GA/AA genotype between HCC patients and controls (crude OR=0.75, 95% CI, 0.59–0.96, P=0.020). Adjustments for age, sex, chronic HBV infection status, smoking, and drinking, this association was more significant (GA vs GG: adjusted OR=0.62, 95% CI, 0.45–0.86, P=0.005 and AA/GA vs GG: adjusted OR=0.64; 95% CI, 0.47–0.88, P=0.007; Table 3). However, we found no association between LEPR rs1137100 G>A and rs1137101 G>A polymorphisms and the risk of HCC in any genetic model (Table 3). We used Bonferroni correction method to conduct a multiple testing. We found the genotype distribution of LEP rs7799039 A>G and LEPR rs6588147 G>A SNPs was still significantly different between HCC patients and cancer-free controls (P=0.006 and 0.007 for LEP rs7799039 A>G, and P=0.005 and 0.007 for LEPR rs6588147 G>A, respectively).

Discussion

Although chronic HBV infection status is associated with the etiology of HCC, the individual’s hereditary factor may influence the susceptibility to HCC. Recently, it is believed that the metabolic disturbance increases the susceptibility to many malignancies.4 Thus, the metabolism-related gene may affect the development of HCC. In this case–control study, we explored the relationship of LEP rs2167270 G>A, rs7799039 A>G, LEPR rs6588147 G>A, rs1137100 G>A, and rs1137101 G>A polymorphisms with the risk of HCC in 584 patients and 923 control subjects in Eastern Chinese Han population. We found that LEP rs7799039 A>G and rs2167270 G>A polymorphisms were associated with the susceptibility of HCC in this population. However, LEPR rs6588147 G>A polymorphism decreased the risk of HCC. To our knowledge, this is the study with the largest sample size on the relationship between LEP rs2167270 G>A, rs7799039 A>G, LEPR rs6588147 G>A, rs1137100 G>A, and rs1137101 G>A polymorphisms and HCC risk. LEP rs7799039 A>G is a promoter SNP, which was suggested it could affect transcriptional level and LEP expression.14 In this study, we found that LEP rs7799039 A>G polymorphism was associated with the susceptibility to HCC in Chinese Han population. Recently, a meta-analysis which included 16 published studies of 6,569 cancer cases and 8,405 controls demonstrated that LEP rs7799039 A>G polymorphism may decrease the risk of cancer.20 In addition, this association between LEP rs7799039 A>G polymorphism and cancer risk was also found in other meta-analyses.16,17 However, the association between LEP rs7799039 A>G polymorphism and the risk of cancer was seldom studied in Asian populations. Clearly, these ambiguous findings suggested that the functions of LEP rs7799039 A>G variants might be different in different races. It was found that the minor allele frequency of LEP rs7799039 A>G polymorphism might alter sharply among different populations (0.201 [Chinese] vs 0.597 [Caucasians]).28 Recently, Romanowski et al reported that LEP rs2167270 G>A polymorphism increased the risk of posttransplant diabetes mellitus.29 LEP rs2167270 G>A is located in 5′-untranslated region and may influence the translation process of LEP mRNA. A functional study demonstrated that serum LEP concentrations in LEP rs2167270 GA genotype were higher than in individuals with rs2167270 GG genotype.30 In this study, the association between LEP rs2167270 G>A polymorphism and increased risk of HCC was found, which was very similar to the findings of the previous meta-analysis.15 In the future, more case–control studies should be carried out to explore the potential association of LEP rs7799039 A>G and LEP rs2167270 G>A polymorphisms with cancer risk in Asians. Slattery et al reported that LEPR rs6588147 AA genotype had a tendency to lower susceptibility of colon cancer in a mixed population.19 We found that rs6588147 A allele may be associated with the decreased susceptibility of HCC, which was similar to previous findings. In our study, after Bonferroni correction test, this association was still significant between HCC patients and cancer-free controls. However, Nyante et al identified that the LEPR rs6588147 G>A polymorphism might confer susceptibility to breast cancer in luminal A subtype.31 Only a few investigations focused on the correlation between LEPR rs6588147 G>A polymorphism and the risk of cancer, especially in Asians. In future, the association of this SNP with cancer susceptibility should be further studied with a large sample size. Also, functional studies are needed to identify the real biologic function of LEPR rs6588147 G>A polymorphism on the development of HCC. There are some limitations in this study. First, since the number of HCC cases and controls was moderate, the power of study might be limited. Second, the HCC cases and controls were both enrolled from local hospitals. Therefore, selection bias should have occurred. Third, for lack of some important data, such as lifestyle, dietary habits, and environmental carcinogens exposure, the interaction of gene–environment was not studied. Fourth, the information available on HCC survival has been insufficient till now; thus, we could not further analyze the potential role of LEP/LEPR functional polymorphisms in HCC progression and prognosis. Fifth, due to lack of sufficient information on height and weight, the body mass index was not considered in this study. Finally, we only selected some functional SNPs in LEP and LEPR genes, and a fine-mapping or Genome Wide Association study focusing on LEP and LEPR genes should be performed to further explore the potential relationship of LEP and LEPR SNPs with the risk of HCC. To sum up, this study has demonstrated that LEP rs7799039 A>G and rs2167270 G>A polymorphisms are genetic risk factors for HCC with various degrees of relationship in an Eastern Chinese Han population. However, LEPR rs6588147 G>A may decrease the risk of HCC. Further epidemiologic case–control studies are needed to assess the interaction of LEP and LEPR genotypes with the exposure to environmental carcinogens, lifestyle, and dietary habits.
  31 in total

1.  Genetic G2548A polymorphism of leptin gene and risk of cancer: a meta-analysis of 6860 cases and 7956 controls.

Authors:  Yunji Yang; Pengcheng Liu; Feng Guo; Run Liu; Yong Yang; Changjia Huang; Hexi Shu; Jinpeng Gong; Ming Cai
Journal:  J BUON       Date:  2014 Oct-Dec       Impact factor: 2.533

2.  Insulin resistance, steatohepatitis, and hepatocellular carcinoma in a new congenic strain of Fatty Liver Shionogi (FLS) mice with the Lep(ob) gene.

Authors:  Masahiko Soga; Setsuko Hashimoto; Yoshio Kishimoto; Tsutomu Hirasawa; Susumu Makino; Shuichiro Inagaki
Journal:  Exp Anim       Date:  2010

3.  Adiponectin and leptin gene polymorphisms in patients with post-transplant diabetes mellitus.

Authors:  Maciej Romanowski; Violetta Dziedziejko; Agnieszka Maciejewska-Karlowska; Marek Sawczuk; Krzysztof Safranow; Leszek Domanski; Andrzej Pawlik
Journal:  Pharmacogenomics       Date:  2015-08-18       Impact factor: 2.533

4.  Cancer statistics in China, 2015.

Authors:  Wanqing Chen; Rongshou Zheng; Peter D Baade; Siwei Zhang; Hongmei Zeng; Freddie Bray; Ahmedin Jemal; Xue Qin Yu; Jie He
Journal:  CA Cancer J Clin       Date:  2016-01-25       Impact factor: 508.702

5.  A polymorphism in the leptin promoter region (-2548 G/A) influences gene expression and adipose tissue secretion of leptin.

Authors:  J Hoffstedt; P Eriksson; S Mottagui-Tabar; P Arner
Journal:  Horm Metab Res       Date:  2002-07       Impact factor: 2.936

Review 6.  Obesity and cancer risk: evidence, mechanisms, and recommendations.

Authors:  Ivana Vucenik; Joseph P Stains
Journal:  Ann N Y Acad Sci       Date:  2012-10       Impact factor: 5.691

7.  Association of LEP G2548A and LEPR Q223R polymorphisms with cancer susceptibility: evidence from a meta-analysis.

Authors:  Jing He; Bo Xi; Rikje Ruiter; Ting-Yan Shi; Mei-Ling Zhu; Meng-Yun Wang; Qiao-Xin Li; Xiao-Yan Zhou; Li-Xin Qiu; Qing-Yi Wei
Journal:  PLoS One       Date:  2013-10-17       Impact factor: 3.240

8.  An open-source software program for performing Bonferroni and related corrections for multiple comparisons.

Authors:  Kyle Lesack; Christopher Naugler
Journal:  J Pathol Inform       Date:  2011-12-26

9.  Polymorphism in LEP and LEPR May Modify Leptin Levels and Represent Risk Factors for Thyroid Cancer.

Authors:  Marjory Alana Marcello; Antonio Ramos Calixto; Jacqueline Fatima Martins de Almeida; Mariana Bonjiorno Martins; Lucas Leite Cunha; Camila Ayume Amano Cavalari; Elba C S Etchebehere; Ligia Vera Montalli da Assumpção; Bruno Geloneze; Andre Lopes Carvalho; Laura Sterian Ward
Journal:  Int J Endocrinol       Date:  2015-02-25       Impact factor: 3.257

Review 10.  Oxidative Stress: A New Target for Pancreatic Cancer Prognosis and Treatment.

Authors:  Javier Martinez-Useros; Weiyao Li; Marticela Cabeza-Morales; Jesus Garcia-Foncillas
Journal:  J Clin Med       Date:  2017-03-09       Impact factor: 4.241

View more
  7 in total

1.  A Variant of Leptin Gene Decreases the Risk of Gastric Cancer in Chinese Individuals: Evidence from a Case-Control Study.

Authors:  Renjie Ma; Qi He
Journal:  Pharmgenomics Pers Med       Date:  2020-09-22

2.  Leptin rs2167270 G > A (G19A) polymorphism may decrease the risk of cancer: A case-control study and meta-analysis involving 19 989 subjects.

Authors:  Jing Yang; Zhihui Zhong; Weifeng Tang; Jianping Chen
Journal:  J Cell Biochem       Date:  2019-01-29       Impact factor: 4.429

3.  Investigation of leptin receptor rs1137101 G>A polymorphism with cancer risk: evidence from 35936 subjects.

Authors:  Guoxiang Rong; Weifeng Tang; Yafeng Wang; Hao Qiu; Shuchen Chen
Journal:  Biosci Rep       Date:  2019-06-28       Impact factor: 3.840

4.  The association of leptin and adiponectin with hepatocellular carcinoma risk and prognosis: a combination of traditional, survival, and dose-response meta-analysis.

Authors:  Lilong Zhang; Qihang Yuan; Man Li; Dongqi Chai; Wenhong Deng; Weixing Wang
Journal:  BMC Cancer       Date:  2020-11-30       Impact factor: 4.430

5.  The Prognosis of Leptin rs2167270 G > A (G19A) Polymorphism in the Risk of Cancer: A Meta-Analysis.

Authors:  Aiqiao Zhang; Shangren Wang; Fujun Zhang; Wei Li; Qian Li; Xiaoqiang Liu
Journal:  Front Oncol       Date:  2021-11-18       Impact factor: 6.244

6.  Association of Leptin Receptor Gene Polymorphisms with Keloids in the Chinese Han Population.

Authors:  Jing Liu; Limin Cai; Zepeng Zhang; Yanli Ma; Yongchen Wang
Journal:  Med Sci Monit       Date:  2021-03-07

7.  The Inter-Relation between Leptin Receptor (Q223R) Gene Polymorphism and the Risk of Egyptian Patients with HCC.

Authors:  Hala A Karam; Sahar S Bessa; Ehab M M Ali; Thoria Diab; Tarek M Mohamed
Journal:  Asian Pac J Cancer Prev       Date:  2020-12-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.